Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABX-101 (Autobahn Therapeutics)
- Development stage
- Unknown
- Lead developer
- Autobahn Therapeutics
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
ABX-101 is a next-generation, brain-penetrant, oral sphingosine 1-phosphate (S1P) receptor modulator being developed by Autobahn Therapeutics for the treatment of neuroimmunologic and neuroinflammatory disorders. It is a small molecule prodrug that utilizes a fatty acid amide hydrolase (FAAH)-mediated brain-targeting platform to achieve high central nervous system (CNS) exposure. By modulating S1P receptors on multiple cell types within the brain, ABX-101 aims to address the underlying pathology of inflammatory CNS diseases while optimizing peripheral immunomodulatory effects. As of 2024, the program is advancing toward Phase 1 clinical development.
02
Targets
S1PR5 (Sphingosine-1-phosphate receptor 5)
Beyond the preview
Go deeper on ABX-101 (Autobahn Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABX-101 (Autobahn Therapeutics).